This earnings season can best be described as 'better than feared.'
Judge 2019 on its own merits -- and do your research.
Techies were falling all over themselves buying NVDA when it was more than double today's quote.
The indices are running into heavy resistance as they hit the levels we last saw in early December, but the bears that keep trying to catch a reversal are providing short-squeeze fuel.
Buy weak names, and hold falling names that were up a lot going into earnings, as they won't be down for long.
Pennsylvania just launched its medical marijuana program, and leading politicians have already started to discuss full legalization.
Rate increases are off the table for now, balance sheet normalization is on hold, and potentially the groundwork is laid for the next round of quantitative easing.
This is one report where the real driver will be what the company says and the tone they take when saying it.
There is a lot of grumbling that the positive response to earnings that were recently cut is not justified.
There is no reason to become a buyer right now -- a close below $42 on heavy volume is likely to precipitate further declines.